A new blood test for colon cancer screening has entered the market, offering an alternative for those who avoid traditional methods. The test detects signs of colorectal cancer through a simple blood draw. However, medical experts caution that its accuracy falls short of the current gold standard.
The blood test works by identifying DNA markers shed by tumors into the bloodstream. For colon cancer, it detects approximately 83% of cases. In comparison, colonoscopy identifies nearly all cancers and precancerous growths. This difference in detection rates is significant for early intervention.
About 50 million Americans are not getting screened for colon cancer at a time when colon-cancer rates are rising. The blood test aims to reach this untested population. Medical professionals see it as a tool to increase overall screening rates, not replace colonoscopy.
Colonoscopy remains the most thorough screening option because it allows doctors to remove polyps during the exam. This preventative step stops cancer before it develops. The blood test can only detect existing cancer, limiting its preventative value.
Insurance coverage remains a barrier for the new blood test. While many plans cover colonoscopy without cost-sharing, the blood test may require a copay. Patients should verify coverage before scheduling.
The test is approved by the FDA for average-risk adults aged 45 and older. It is not recommended for high-risk individuals, such as those with a family history of colon cancer. Those patients should stick with colonoscopy for maximum protection.
Choosing a screening method ultimately depends on personal preference and risk profile. For those avoiding any screening entirely, a blood test offers a better option than none. For comprehensive detection, colonoscopy remains the superior choice.
